LT5138B - Epotilono analogo polimorfinės formos - Google Patents

Epotilono analogo polimorfinės formos Download PDF

Info

Publication number
LT5138B
LT5138B LT2003017A LT2003017A LT5138B LT 5138 B LT5138 B LT 5138B LT 2003017 A LT2003017 A LT 2003017A LT 2003017 A LT2003017 A LT 2003017A LT 5138 B LT5138 B LT 5138B
Authority
LT
Lithuania
Prior art keywords
crystalline
hours
mixture
formula
analogue
Prior art date
Application number
LT2003017A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT2003017A (en
Inventor
John D. Dimarco
Jack Z. Gougoutas
Imre M. Vitez
Martha Davidovich
Michael Galella
Denis Favreau
Timothy M. Malloy
Zhenrong Guo
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22845469&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT5138(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of LT2003017A publication Critical patent/LT2003017A/xx
Publication of LT5138B publication Critical patent/LT5138B/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LT2003017A 2000-08-16 2003-02-25 Epotilono analogo polimorfinės formos LT5138B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22559000P 2000-08-16 2000-08-16

Publications (2)

Publication Number Publication Date
LT2003017A LT2003017A (en) 2004-03-25
LT5138B true LT5138B (lt) 2004-06-25

Family

ID=22845469

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2003017A LT5138B (lt) 2000-08-16 2003-02-25 Epotilono analogo polimorfinės formos

Country Status (42)

Country Link
US (4) US6689802B2 (no)
EP (1) EP1309597B1 (no)
JP (1) JP5046467B2 (no)
KR (1) KR100810342B1 (no)
CN (1) CN1269821C (no)
AR (1) AR034259A1 (no)
AT (1) ATE366735T1 (no)
AU (2) AU2001281082B2 (no)
BG (1) BG66132B1 (no)
BR (1) BR0113234A (no)
CA (1) CA2418109C (no)
CY (1) CY1107758T1 (no)
CZ (1) CZ305523B6 (no)
DE (1) DE60129334T2 (no)
DK (1) DK1309597T3 (no)
EE (1) EE05273B1 (no)
ES (1) ES2288518T3 (no)
GE (1) GEP20053495B (no)
HK (1) HK1052010A1 (no)
HR (1) HRP20030190B1 (no)
HU (1) HU229314B1 (no)
IL (2) IL153993A0 (no)
IS (1) IS2845B (no)
LT (1) LT5138B (no)
LV (1) LV13032B (no)
MX (1) MXPA03001431A (no)
MY (1) MY134129A (no)
NO (1) NO328500B1 (no)
NZ (1) NZ523722A (no)
PE (1) PE20020290A1 (no)
PL (1) PL205628B1 (no)
PT (1) PT1309597E (no)
RO (1) RO123296B1 (no)
RU (1) RU2272039C2 (no)
SI (1) SI21100B (no)
SK (1) SK287876B6 (no)
TW (1) TWI320040B (no)
UA (1) UA75365C2 (no)
UY (1) UY26886A1 (no)
WO (1) WO2002014323A2 (no)
YU (1) YU12103A (no)
ZA (1) ZA200300522B (no)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4579351B2 (ja) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
PL207720B1 (pl) * 2001-01-25 2011-01-31 Bristol Myers Squibb Co Sposób przygotowania preparatu farmaceutycznego i jego zastosowanie, farmaceutyczny produkt oraz sposób wytwarzania kompozycji farmaceutycznej
JP2004521122A (ja) * 2001-01-25 2004-07-15 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン類似体の非経口製剤
EE200300396A (et) 2001-02-20 2003-12-15 Bristol-Myers Squibb Company Epotilooni derivaatide kasutamine refraktaarsete kasvajate raviks
CZ305799B6 (cs) * 2001-03-14 2016-03-23 Bristol-Myers Squibb Company Kombinace analogů epothilonu a chemoterapeutických činidel pro léčení proliferačních nemocí
CN100402029C (zh) * 2002-03-08 2008-07-16 诺瓦提斯公司 包含埃坡霉素衍生物和烷化剂的组合
EP1506203B1 (en) * 2002-08-23 2007-01-03 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
US20060134214A1 (en) * 2004-11-18 2006-06-22 Ismat Ullah Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
ATE397442T1 (de) 2004-11-18 2008-06-15 Bristol Myers Squibb Co Magensaftresistent beschichtetes pellet mit ixabepilon
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
AU2006336468B2 (en) 2005-02-11 2012-04-12 University Of Southern California Method of expressing proteins with disulfide bridges
ES2522895T3 (es) * 2005-03-03 2014-11-19 Alfa Wassermann S.P.A. Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
US7693596B2 (en) 2005-12-14 2010-04-06 Dell Products L.P. System and method for configuring information handling system integrated circuits
US20080286325A1 (en) * 2006-01-05 2008-11-20 Med Institute, Inc. Cyclodextrin elution media for medical device coatings comprising a taxane therapeutic agent
US7919108B2 (en) * 2006-03-10 2011-04-05 Cook Incorporated Taxane coatings for implantable medical devices
US7875284B2 (en) * 2006-03-10 2011-01-25 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
CA2647565A1 (en) 2006-03-31 2007-10-18 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP2029156A4 (en) 2006-05-01 2010-07-21 Univ Southern California POLY THERAPY FOR TREATING CANCER
WO2007131366A1 (en) 2006-05-16 2007-11-22 Aegera Therapeutics Inc. Iap bir domain binding compounds
WO2008019820A2 (en) * 2006-08-16 2008-02-21 Novartis Ag Crystal form of epothilone b and use in pharmaceutical compositions
US8463852B2 (en) * 2006-10-06 2013-06-11 Oracle International Corporation Groupware portlets for integrating a portal with groupware systems
US20110124690A1 (en) * 2007-02-23 2011-05-26 Danishefsky Samuel J Compositions and methods for treating cancer or a neurotrophic disorder
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
EP2070521A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Surface-modified nanoparticles
WO2010056901A2 (en) 2008-11-13 2010-05-20 University Of Southern California Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
AU2011214057B2 (en) 2010-02-12 2016-11-17 Pharmascience Inc. IAP BIR domain binding compounds
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
JP2013527239A (ja) * 2010-06-01 2013-06-27 プラス・ケミカルス・エスアー イクサベピロンの固体形
CA2858806A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014009426A2 (en) 2012-07-13 2014-01-16 Innate Pharma Screening of conjugated antibodies
EP3564259A3 (en) 2012-11-09 2020-02-12 Innate Pharma Recognition tags for tgase-mediated conjugation
CN103183681B (zh) * 2013-03-06 2016-01-13 浙江海正药业股份有限公司 伊沙匹隆的新晶型及其制备方法
EP2968582B1 (en) 2013-03-15 2020-07-01 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
EP3010547B1 (en) 2013-06-20 2021-04-21 Innate Pharma Enzymatic conjugation of polypeptides
EP3010548A1 (en) 2013-06-21 2016-04-27 Innate Pharma Enzymatic conjugation of polypeptides
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues
US20230062248A1 (en) 2020-01-31 2023-03-02 Allarity Therapeutics Europe ApS Methods for predicting ixabepilone responsiveness in cancer patients
CN112409366A (zh) * 2020-11-30 2021-02-26 湖北宏中药业股份有限公司 一种伊沙匹隆二聚体的高收率制备方法
CN112457320A (zh) * 2020-11-30 2021-03-09 湖北宏中药业股份有限公司 一种提高伊沙匹隆合成反应速率的方法
CN112375085A (zh) * 2020-11-30 2021-02-19 湖北宏中药业股份有限公司 一种伊沙匹隆反应液的高收率高纯度处理方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010121A1 (de) 1991-11-19 1993-05-27 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone, deren herstellungsverfahren und ihre verwendung als arzneimittel und pflanzenschützende mittel
WO1997019086A1 (de) 1995-11-17 1997-05-29 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilonderivate, herstellung und verwendung
US9170582B2 (en) 2013-12-19 2015-10-27 Google Inc. Path based power generation control for an aerial vehicle

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1000809A (en) * 1960-11-02 1965-08-11 James Oakes & Company Riddings Pipe manufacture
DE2308418B2 (de) * 1972-06-21 1976-04-08 Petzetakis, Aristovoulos George, Moschaton, Piräus (Griechenland) Verfahren und vorrichtung zum herstellen eines insbesondere grosskalibrigen rohres aus thermoplastischem kunststoff
JPS5240337B2 (no) * 1973-01-29 1977-10-12
SE386365B (sv) * 1973-07-25 1976-08-09 L Brendling Behallare av plast, gummi eller annat bojligt material, spec. avsedd for uppsamling av urin och/eller fekalier
JPS6398413A (ja) * 1986-10-15 1988-04-28 Smc Corp 二重管およびその連続製造法
DE3927569A1 (de) * 1989-08-21 1991-02-28 Fritz Egger Gmbh Elektroabscheider zum abscheiden von schwebstoffen aus gasen
DE3939714A1 (de) * 1989-12-01 1991-06-06 Baedje K H Meteor Gummiwerke Schlauch
AU6431790A (en) * 1990-01-05 1991-08-05 Orscheln Co. Flexible synthetic plastic conduit
DE4206096A1 (de) * 1992-02-27 1993-09-02 Wolf Woco & Co Franz J Koaxialrohr
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
DE19636343C1 (de) 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
AU716610B2 (en) 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
PT941227E (pt) * 1996-11-18 2004-08-31 Biotechnolog Forschung Mbh Gbf Epothilona d sua preparacao e sua utilizacao como agente citostatico ou como agente de proteccao fitossanitaria
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
JP4579351B2 (ja) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
CN1128803C (zh) 1997-02-25 2003-11-26 生物技术研究有限公司(Gbf) 环氧噻嗪酮b－n－氧化物及其制备方法
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
ATE225783T1 (de) 1997-04-18 2002-10-15 Studiengesellschaft Kohle Mbh Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
JP2001510189A (ja) 1997-07-16 2001-07-31 シエーリング アクチエンゲゼルシヤフト チアゾール誘導体、その製造法および使用
JP2001512723A (ja) 1997-08-09 2001-08-28 シエーリング アクチエンゲゼルシヤフト 新規エポチロン誘導体、その製法およびその薬学的使用
DE19747580A1 (de) 1997-10-28 1999-04-29 Siemens Ag Rangierfeld mit Anschlußleiste
US6365749B1 (en) * 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
MY125921A (en) 1998-02-05 2006-08-30 Novartis Ag Compositions containing organic compounds
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
DE19807505A1 (de) 1998-02-21 1999-08-26 Roland Man Druckmasch Bogenrotationsdruckmaschine mit Druckeinheiten für den Mehrfarbendruck und wenigstens einer Beschichtungseinheit
MXPA00008365A (es) 1998-02-25 2002-11-07 Sloan Kettering Inst Cancer Sintesis de epotilonas, intermediarios y analogos de las mismas.
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
AU5036999A (en) 1998-06-30 2000-01-17 Schering Aktiengesellschaft Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
WO2000009317A1 (en) * 1998-08-12 2000-02-24 Proteus Inc. Ribbed core dual wall structure
JP2002533346A (ja) 1998-12-22 2002-10-08 ノバルティス アクチエンゲゼルシャフト エポシロン誘導体およびそれらの抗腫瘍剤としての使用
AR023792A1 (es) 1999-04-30 2002-09-04 Bayer Schering Pharma Ag Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
US6605559B1 (en) 1999-09-29 2003-08-12 Daihatsu Motor Co., Ltd. Dimethyl ether reforming catalyst
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
HU229349B1 (en) 2001-01-25 2013-11-28 Bristol Myers Squibb Co Methods for preparation of pharmaceutical composition containing epothilone analogs useful for treatment of cancer
JP2004521122A (ja) 2001-01-25 2004-07-15 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン類似体の非経口製剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010121A1 (de) 1991-11-19 1993-05-27 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone, deren herstellungsverfahren und ihre verwendung als arzneimittel und pflanzenschützende mittel
WO1997019086A1 (de) 1995-11-17 1997-05-29 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilonderivate, herstellung und verwendung
US9170582B2 (en) 2013-12-19 2015-10-27 Google Inc. Path based power generation control for an aerial vehicle

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D.-S. SU, S.B. HORWITZ, ET AL.: "Structure-activity relationships of the epothilones and the first in vivo comparison with Paclitaxel", ANGEW. CHEM., 1997, pages 2093 - 2096, XP002916075, DOI: doi:10.1002/anie.199720931
HOEFLE G. ET AL.: "Epothilone A and Bâ€"Novel 16-Membered Macrolides with Cytotoxic Activity: Isolation, Crystal Structure, and Conformation in Solution", ANGEW. CHEM., 1996, pages 1567 - 1569
K. C. NICOLAOU ET AL.: "Total synthesis of 26-hydroxyepothilone B and related analogues", ANGEW. CHEM., 1997, pages 2097 - 2103

Also Published As

Publication number Publication date
SK287876B6 (sk) 2012-02-03
IL153993A (en) 2009-07-20
RO123296B1 (ro) 2011-06-30
SI21100A (sl) 2003-06-30
US6689802B2 (en) 2004-02-10
CN1269821C (zh) 2006-08-16
KR20030022411A (ko) 2003-03-15
IS6714A (is) 2003-02-11
PL205628B1 (pl) 2010-05-31
ES2288518T3 (es) 2008-01-16
NO20030707L (no) 2003-04-15
US6982276B2 (en) 2006-01-03
BG66132B1 (bg) 2011-06-30
MXPA03001431A (es) 2004-05-04
HUP0300826A2 (hu) 2003-09-29
USRE39251E1 (en) 2006-08-29
NZ523722A (en) 2005-04-29
UY26886A1 (es) 2002-03-22
GEP20053495B (en) 2005-04-25
HRP20030190B1 (en) 2011-07-31
CN1468243A (zh) 2004-01-14
LV13032B (en) 2003-12-20
MY134129A (en) 2007-11-30
PL365610A1 (en) 2005-01-10
PT1309597E (pt) 2007-08-22
KR100810342B1 (ko) 2008-03-07
JP2004506638A (ja) 2004-03-04
IL153993A0 (en) 2003-07-31
BG107467A (bg) 2003-09-30
US7153879B2 (en) 2006-12-26
HRP20030190A2 (en) 2003-04-30
HUP0300826A3 (en) 2005-05-30
DE60129334D1 (en) 2007-08-23
HU229314B1 (en) 2013-10-28
NO20030707D0 (no) 2003-02-14
ZA200300522B (en) 2004-04-20
CZ2003418A3 (cs) 2004-01-14
WO2002014323A2 (en) 2002-02-21
US20040157897A1 (en) 2004-08-12
TWI320040B (en) 2010-02-01
DK1309597T3 (da) 2007-10-22
EP1309597B1 (en) 2007-07-11
HK1052010A1 (en) 2003-08-29
US20060063815A1 (en) 2006-03-23
CA2418109C (en) 2011-09-27
AU2001281082B2 (en) 2007-01-04
IS2845B (is) 2013-08-15
PE20020290A1 (es) 2002-04-03
BR0113234A (pt) 2004-02-25
EP1309597A2 (en) 2003-05-14
NO328500B1 (no) 2010-03-01
EE05273B1 (et) 2010-02-15
UA75365C2 (en) 2006-04-17
DE60129334T2 (de) 2008-04-03
CA2418109A1 (en) 2002-02-21
YU12103A (sh) 2006-08-17
LT2003017A (en) 2004-03-25
AR034259A1 (es) 2004-02-18
JP5046467B2 (ja) 2012-10-10
ATE366735T1 (de) 2007-08-15
WO2002014323A3 (en) 2002-05-02
EE200300063A (et) 2004-12-15
US20020188014A1 (en) 2002-12-12
RU2272039C2 (ru) 2006-03-20
CY1107758T1 (el) 2013-06-19
SK1342003A3 (en) 2003-09-11
SI21100B (sl) 2009-12-31
AU8108201A (en) 2002-02-25
CZ305523B6 (cs) 2015-11-18

Similar Documents

Publication Publication Date Title
LT5138B (lt) Epotilono analogo polimorfinės formos
AU2001281082A1 (en) Polymorphs of an epothilone analog
DE60132309T2 (de) Amin-derivate zur behandlung von apoptosis
CN101687827B (zh) 环状基团取代的氨基二氢噻嗪衍生物
DE69832294T2 (de) Epothilonderivate
AU2014278428B2 (en) Processes of making and crystalline forms of a MDM2 inhibitor
WO2022268230A1 (zh) 作为kif18a抑制剂的化合物
CN105308030A (zh) 烷基、氟烷基-1,4-苯并二氮杂*酮化合物
EP1181294B1 (de) Neue derivate und analoga von galanthamin
TW202214654A (zh) 稠合喹唑啉類衍生物、其製備方法及其在醫藥上的應用
CN115650974B (zh) N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-顺式戊二烯酰胺衍生物及应用
JPH06199861A (ja) マイトマイシン誘導体

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20160801